The scientist’s investigation covers issues in Radiation therapy, Lung cancer, Nuclear medicine, Internal medicine and Oncology. His Radiation therapy study combines topics in areas such as Positron emission tomography, Prospective cohort study and Cancer. His Lung cancer research integrates issues from Radiation treatment planning, Stage, Surgery, Carcinoma and Primary tumor.
Dirk De Ruysscher interconnects Tomography and Performance status in the investigation of issues within Nuclear medicine. His research links Gastroenterology with Internal medicine. His Oncology research is multidisciplinary, incorporating perspectives in Survival analysis, Hypoxia, Disease and Evidence-based medicine.
His primary areas of study are Radiation therapy, Internal medicine, Lung cancer, Oncology and Radiology. To a larger extent, he studies Surgery with the aim of understanding Radiation therapy. Dirk De Ruysscher has included themes like Stage, Prospective cohort study, Carcinoma and Randomized controlled trial in his Lung cancer study.
His work carried out in the field of Oncology brings together such families of science as Locally advanced, Clinical trial, Breast cancer and Immunotherapy. His primary area of study in Radiology is in the field of Radiation treatment planning. The Nuclear medicine study which covers Lung that intersects with Radiation induced.
His main research concerns Internal medicine, Oncology, Radiation therapy, Lung cancer and Non small cell. Internal medicine is represented through his Chemotherapy, Stage, Prophylactic cranial irradiation, Performance status and Randomized controlled trial research. His Stage research incorporates themes from Chemoradiotherapy and Incidence.
He works mostly in the field of Oncology, limiting it down to topics relating to Cancer and, in certain cases, Prospective cohort study. His Radiation therapy study is associated with Radiology. In his study, Radiosurgery is strongly linked to Quality of life, which falls under the umbrella field of Lung cancer.
Dirk De Ruysscher mostly deals with Internal medicine, Radiation therapy, Lung cancer, Oncology and Radiology. His research investigates the connection with Radiation therapy and areas like Pneumonitis which intersect with concerns in Esophageal cancer. His studies in Lung cancer integrate themes in fields like Chemoradiotherapy, Quality of life and Hazard ratio.
His research in Hazard ratio intersects with topics in Bioelectrical impedance analysis, Surgery, Weakness, Brain metastasis and Mass index. His studies deal with areas such as Cancer, Ipilimumab, Immunotherapy, Clinical trial and Carcinoma as well as Oncology. His Radiology research includes elements of Mastectomy and Occult.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J. Vansteenkiste;D. De Ruysscher;W.E.E. Eberhardt;E. Lim.
Annals of Oncology (2013)
Small Cell Lung Cancer
Jan P van Meerbeeck;Dean A Fennell;Dirk K M De Ruysscher.
The Lancet (2011)
Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
M Reck;S Popat;N Reinmuth;Dirk De Ruysscher.
Annals of Oncology (2012)
ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy)
Alessandro Brunelli;Anne Charloux;Chris Thomas Bolliger;Gaetano Rocco.
European Respiratory Journal (2009)
Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
M Früh;Dirk De Ruysscher;S Popat;L Crinò.
Annals of Oncology (2013)
The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant
Kobe Reynders;Tim Illidge;Shankar Siva;Shankar Siva;Joe Y. Chang.
Cancer Treatment Reviews (2015)
2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up
J. Vansteenkiste;L. Crinò;C. Dooms;J. Y. Douillard.
Annals of Oncology (2014)
Selection of patients for radiotherapy with protons aiming at reduction of side effects: the model-based approach.
Johannes A. Langendijk;Philippe Lambin;Dirk De Ruysscher;Joachim Widder.
Radiotherapy and Oncology (2013)
Time Between the First Day of Chemotherapy and the Last Day of Chest Radiation Is the Most Important Predictor of Survival in Limited-Disease Small-Cell Lung Cancer
Dirk De Ruysscher;Madelon Pijls-Johannesma;Søren M. Bentzen;André Minken.
Journal of Clinical Oncology (2006)
Predicting outcomes in radiation oncology--multifactorial decision support systems
Philippe Lambin;Ruud G. P. M. van Stiphout;Maud H. W. Starmans;Emmanuel Rios-Velazquez.
Nature Reviews Clinical Oncology (2013)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: